CXC chemokine receptor 7 ameliorates renal fibrosis by inhibiting β-catenin signaling and epithelial-to-mesenchymal transition in tubular epithelial cells

References

• Carney EF. The impact of chronic kidney disease on global health. Nat Rev Nephrol. 2020;16(5):1–13. doi:10.1038/s41581-020-0268-7.
   PubMed Web of Science ®Google Scholar
• Huang R, Fu P, Ma L. Kidney fibrosis: from mechanisms to therapeutic medicines. Sig Transduct Target Ther. 2023;8(1):129. doi:10.1038/s41392-023-01379-7.
   PubMed Web of Science ®Google Scholar
• Lanzon B, Martin-Taboada M, Castro-Alves V, et al. Lipidomic and metabolomic signature of progression of chronic kidney disease in patients with severe obesity. Metabolites. 2021;11(12):836. doi:10.3390/metabo11120836.
   PubMed Web of Science ®Google Scholar
• Hughes CE, Nibbs R. A guide to chemokines and their receptors. Febs J. 2018;285(16):2944–2971. doi:10.1111/febs.14466.
   PubMed Web of Science ®Google Scholar
• Wu F, Sun C, Lu J. The role of chemokine receptors in renal fibrosis. Rev Physiol Biochem Pharmacol. 2020;177:1–24. doi:10.1007/112_2020_21.
   PubMed Web of Science ®Google Scholar
• Liu P, Li X, Lv W, et al. Inhibition of CXCL1-CXCR2 axis ameliorates cisplatin-induced acute kidney injury by mediating inflammatory response. Biomed Pharmacother. 2020;122:109693. doi:10.1016/j.biopha.2019.109693.
   PubMed Web of Science ®Google Scholar
• Meng P, Huang J, Ling X, et al. CXC chemokine receptor 2 accelerates tubular cell senescence and renal fibrosis via beta-Catenin-induced mitochondrial dysfunction. Front Cell Dev Biol. 2022;10:862675. doi:10.3389/fcell.2022.862675.
   PubMed Web of Science ®Google Scholar
• Wang D, Chen X, Fu M, et al. Tacrolimus increases the expression level of the chemokine receptor CXCR2 to promote renal fibrosis progression. Int J Mol Med. 2019;44(6):2181–2188. doi:10.3892/ijmm.2019.4368.
   PubMed Web of Science ®Google Scholar
• Liu Y, Feng Q, Miao J, et al. C-X-C motif chemokine receptor 4 aggravates renal fibrosis through activating JAK/STAT/GSK3beta/beta-catenin pathway. J Cell Mol Med. 2020;24(7):3837–3855. doi:10.1111/jcmm.14973.
   PubMed Web of Science ®Google Scholar
• Mo H, Ren Q, Song D, et al. CXCR4 induces podocyte injury and proteinuria by activating beta-catenin signaling. Theranostics. 2022;12(2):767–781. doi:10.7150/thno.65948.
   PubMed Web of Science ®Google Scholar
• Mo H, Wu Q, Miao J, et al. C-X-C chemokine receptor type 4 plays a crucial role in mediating oxidative Stress-Induced podocyte injury. Antioxid Redox Signal. 2017;27(6):345–362. doi:10.1089/ars.2016.6758.
   PubMed Web of Science ®Google Scholar
• Wu Y, An C, Jin X, et al. Disruption of CXCR6 ameliorates kidney inflammation and fibrosis in deoxycorticosterone acetate/salt hypertension. Sci Rep. 2020;10(1):133. doi:10.1038/s41598-019-56933-7.
   PubMed Web of Science ®Google Scholar
• Xia Y, Jin X, Yan J, et al. CXCR6 plays a critical role in angiotensin II-induced renal injury and fibrosis. Arterioscler Thromb Vasc Biol. 2014;34(7):1422–1428. doi:10.1161/ATVBAHA.113.303172.
   PubMed Web of Science ®Google Scholar
• Lounsbury N. Advances in CXCR7 modulators. Pharmaceuticals (Basel). 2020;13(2):33. doi:10.3390/ph13020033.
   PubMedGoogle Scholar
• Wang C, Chen W, Shen J. CXCR7 targeting and its major disease relevance. Front Pharmacol. 2018;9:641. doi:10.3389/fphar.2018.00641.
   PubMed Web of Science ®Google Scholar
• Guan S, Zhou J. CXCR7 attenuates the TGF-beta-induced endothelial-to-mesenchymal transition and pulmonary fibrosis. Mol Biosyst. 2017;13(10):2116–2124. doi:10.1039/c7mb00247e.
   PubMedGoogle Scholar
• Shi A, Wang T, Jia M, et al. Effects of SDF-1/CXCR7 on the migration, invasion and epithelial-Mesenchymal transition of gastric cancer cells. Front Genet. 2021;12:760048. doi:10.3389/fgene.2021.760048.
   PubMed Web of Science ®Google Scholar
• Cao Z, Lis R, Ginsberg M, et al. Targeting of the pulmonary capillary vascular niche promotes lung alveolar repair and ameliorates fibrosis. Nat Med. 2016;22(2):154–162. doi:10.1038/nm.4035.
   PubMed Web of Science ®Google Scholar
• Menhaji-Klotz E, Hesp KD, Londregan AT, et al. Discovery of a novel small-Molecule modulator of C-X-C chemokine receptor type 7 as a treatment for cardiac fibrosis. J Med Chem. 2018;61(8):3685–3696. doi:10.1021/acs.jmedchem.8b00190.
   PubMed Web of Science ®Google Scholar
• Shen M, Feng Y, Wang J, et al. CXCR7 inhibits fibrosis via wnt/beta-Catenin pathways during the process of angiogenesis in human umbilical vein endothelial cells. Biomed Res Int. 2020;2020:1216926–1216910. doi:10.1155/2020/1216926.
   PubMed Web of Science ®Google Scholar
• Zhou L, Zhou S, Yang P, et al. Targeted inhibition of the type 2 cannabinoid receptor is a novel approach to reduce renal fibrosis. Kidney Int. 2018;94(4):756–772. doi:10.1016/j.kint.2018.05.023.
   PubMed Web of Science ®Google Scholar
• Kim KK, Sheppard D, Chapman HA. TGF-beta1 signaling and tissue fibrosis. Cold Spring Harb Perspect Biol. 2018;10(4):a022293. doi:10.1101/cshperspect.a022293.
   PubMed Web of Science ®Google Scholar
• Humphreys BD. Mechanisms of renal fibrosis. Annu Rev Physiol. 2018;80(1):309–326. doi:10.1146/annurev-physiol-022516-034227.
   PubMedGoogle Scholar
• Schunk SJ, Floege J, Fliser D, et al. WNT-beta-catenin signalling - a versatile player in kidney injury and repair. Nat Rev Nephrol. 2021;17(3):172–184. doi:10.1038/s41581-020-00343-w.
   PubMed Web of Science ®Google Scholar
• Nlandu-Khodo S, Osaki Y, Scarfe L, et al. Tubular beta-catenin and FoxO3 interactions protect in chronic kidney disease. JCI Insight. 2020;5(10):e135454. doi:10.1172/jci.insight.135454.
   PubMed Web of Science ®Google Scholar